Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In this Journal of Clinical Oncology study, anetumab ravtansine yielded manageable safety, tolerability, pharmacokinetics, and clinical activity in a study of 148 heavily pretreated patients with mesothelin-expressing solid tumors.
Gastroenterology May 18th 2020
Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.
Hematology May 18th 2020
This feature article from the BMJ discusses how and why American oncologists are rushing to prioritize the patients at greatest risk, institute new protections, and learn from their collective experiences during the COVID-19 pandemic.
Family Medicine/General Practice May 4th 2020
Although the findings reported in Blood should be considered as hypothesis-generating and preliminary in nature, a small clinical trial suggested ibrutinib may protect against lung injury and improve pulmonary function in hypoxic patients with COVID-19.
Allergy & Immunology April 27th 2020
Beyond converting to telehealth platforms and limiting in-office visits, the Best Practices Committee of the NCCN shares essential approaches to help mitigate the transmission of COVID-19 among patients with cancer and the health care workers who treat them.
Allergy & Immunology April 20th 2020
This study in Cancer suggests the possibility, pointing to qualitative results of clinical trial principal investigators, research staff, referring clinicians, and cancer center leaders regarding their attitudes and experiences with enrolling minority patients in cancer clinical trials.
Family Medicine/General Practice April 20th 2020